Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Very little volume here! Is this a medical stock or what exactly are they doing?
If they hire a new doctor we see 0.05 again. That will be a sign that research team is up and running again.
“We had this discussion before, 3i cannot hold more than 9.99% due to the blocker. “
That’s what I said.
We had this discussion before, 3i cannot hold more than 9.99% due to the blocker.
They only hold and file a 13 when they create enough shares in the O/S through their LOAN conversion dilution to the float.
So, 3i converts some to the open market then keep some to maintain their 9.99%. The rest covert to whoever will buy them over .01 for the most part. Usually its when the price organically starts to rise because they manufacture the subtle quiet period between cycles.
Either way, unless CNBX starts making money and plans to release info, the debt holder will maintain this YO-YO cycle, so just play it when able.
Based on remaining debt, 3i will convert probably 150-300M, just a guess. Could be less or more.
At least 3i hasn’t asked for another promissory note for failure to pay.
SC 13G/A ….3i Management LLC, are the company’s financier’s.
If you look at the original SC 13G from 03/06/2023 they had less shares, but always less than 10%. Today’s amendment looks like now they have more shares to sell?
Doesn’t mean they have to sell them, but why would they get them? I imagine if the company started making moves they would hold and let the price rise? It’s a different kind of dilutive financing, but actually pretty good if the company does well??
That’s what I think??? IMO
Everyone should read it for themselves…..
https://www.otcmarkets.com/otcapi/company/financial-report/392190/content
The company holding the shares is the note company.
If i read this correctly they have almost 30% of the shares available.
https://ih.advfn.com/stock-market/USOTC/cnbx-pharmaceuticals-qb-CNBX/stock-news/93269065/form-sc-13g-a-statement-of-acquisition-of-benefi
Interesting filing this could have been some of the recent volume in the stock.
Not me, yet. 320K shares here. Looking to add more next week.
The good news with that volume, there was no increase in O/S for CNBX.
Anyone else own a million plus shares here?
Interesting move with volume
Market Cap Market Cap
354,047
02/07/2024
Authorized Shares
900,000,000
02/05/2024
Outstanding Shares
31,111,352
02/05/2024
Restricted
733,640
02/05/2024
Unrestricted
30,377,712
02/05/2024
Held at DTC
30,367,900
02/05/2024
Float
4,196,841
05/26/2023
“Let’s hope for some good communication from the company”
Ya, their website needs updating from 2022. And can’t see much happening with the war going imo
Just waiting……….
“WHO’s protecting the Q status? “
Example; one of the requirements for uplisting is a company needs at least 4 mm’s in that role.
“I don’t see ANYTHING from the company justifying why .01 is some all important level that WILL be protected. “
Do you realize that they JUST made the payment for QB listing? That’s the justification.
So we wait for news……..
Well, with all due respect, WHO’s protecting the Q status? The computer algorithms that the MM’s are using don’t give a damn where it closes one way or the other and I haven’t seen the company releasing any news. And the volume has been pretty pathetic. So where’s this mythical support coming from? Yeah, I understand that .01 is an important support level (except that it has to stay under it for longer than one close). I also see it went to .0085 before retail (me being one of them) stepped in.
I don’t see ANYTHING from the company justifying why .01 is some all important level that WILL be protected.
Time will tell. Let’s hope for some good communication from the company - or ANY communication, for that matter.
Share price didn't budge
Someone grabbed almost 700k shares
Based on what?. I haven't seen any PR's
They ran it up to 1.8 cents....gather a short position and then convert shares. So noteholder is winning in two ways here.
Just my opinion.
.01 is QB support…What didn’t you understand?
But you never know what can happen. That’s what the question mark (?) means
He is probably stating it will stay above .01 like it has for nearly a year. CNBX or someone has shown they intend to preserve the QB status requirements.
You were saying?
Otcn on the ask is never a good sign. Note holder most likely otcn.
Protecting the QB is important so I don’t see it going much lower?
Looks like the sells are becoming buys. Smart money, maybe this is a sign that the CEO will open his fucking trap soon.
This could be some sellers or note holders but I am not too worried. If you know the history of this stock it will go back up very quickly. Go CNBX.
Curious whether the company will intervene to protect the QB status?
Note holder may not GAF anymore.
I'm sure there are some frustrated traders. Or note holders.
someone is selling today
Holding steady, no buyers no sellers. Hopefully a strong signal.
It was a question on the wrong board...
Finally life in the otc is coming alive!
Present evidence of your claim please.
niceeeeeeeeeeeeeeeee.low float gem here
400K shares at 0.014. Let’s do this 💪
Some nice volume this morning, looks to be mainly buys.
Time to start getting some momo then maybe the tight lipped CEO will release something with substance.
Didn't they just anniunce a r=s?
Updating the website or some news would really help!!
Let’s see if tomorrow the market maters are just still trading amongst themselves as always. Would be nice to see a move up past .02 and hold.
Splitting hairs
Followers
|
184
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
7445
|
Created
|
11/29/09
|
Type
|
Free
|
Moderators mrinvestor08 |
Outstanding: 4,966,197
Float: 4,196,841
Bringing Cannabinoid Diagnostics to Personalized Cancer Care
Cannabics Pharmaceuticals Inc. (CNBX), a U.S-based public company, is dedicated to the development of personalized diagnostic tools, aimed to provide supportive data for practitioners and patients regarding cannabinoid based therapy. The Company’s R&D is based in Israel, where it is licensed by the Ministry of Health for its work in both scientific and clinical research. The Company’s focus is on harnessing the therapeutic properties of natural Cannabinoid formulations. Cannabics engages in delivering the maximum amount of supportive data for cancer patients and their doctors, utilizing advanced screening systems and personalized bioinformatics tools.
Cannabics SR' Capsules, Technology Description - Route of administration
There is a growing number of patients, worldwide, who could benefit from the therapeutic properties of cannabinoids. The unmet need of these patients is a safe, standardized and easy to administer cannabinoid-based therapy. Cannabinoid administration is mainly through smoking, vaporizing, sublingual and oral. While clinical studies show contradictory data regarding a correlation between smoking cannabis and respiratory diseases, most physicians agree that smoking medical cannabis, while having its benefits, is not a healthy nor standardized therapy.
The pharmacokinetics of THC varies as a function of its route of administration. Pulmonary assimilation of inhaled THC causes a maximum plasma concentration within minutes; psychotropic effects start within seconds to a few minutes, reach a maximum after 15–30 minutes, and taper off within 2–3 hours. Following oral ingestion, psychotropic effects set in with a delay of 30–90 minutes, reach their maximum after 2–3 hours and last for about 4–12 hours, depending on dose and specific effect. Another common route of administration is sublingually. Pure cannabinoids are extracted from the raw plant, dissolved in different oils and administered with a dropper. The beneficial effect of sublingual oil administration is 2-4 hours with a fast onset due to quick absorption through the oral cavity.
The most common oral administration of cannabinoids is through eating edibles, mainly, cookies, chocolate bars and lozenges. Since absorption is attenuated when cannabinoids are ingested orally, Edibles usually contain high dosages of cannabinoids (50-300mg). The high dosage may cause undesirable side effects, mainly, dizziness, anxiety and dissociation. These side effects cause many patients to withdraw from the therapeutic process. The oral administration route has the longest beneficial effect (4-8 hours) and lacks the undesirable effects of smoking.
Technology currently envisions the licensing of three different formulations: capsules with a 10:1 CBD to THC ratio, a 10:1 THC to CBD ratio and a balanced formulation with 1:1 THC:CBD.
Cannabics Pharmaceuticals Inc. does not manufacture, distribute, dispense or possess any controlled substances, including cannabis or cannabis based preparations.
Dr. Eyal Ballan, Chief scientist of Cannabics Pharmaceuticals stated, "Our mission is to find the right balance between efficacy on the one hand and the elimination of undesired psychoactive effects on other."
The Cannabics 5mg THC capsule is currently being evaluated by the company in a clinical study as a palliative treatment, which is conducted by the oncology department at the prestigious Rambam Medical Center in northern Israel and under strict regulations of the Ministry of Health, by whom Cannabics Pharmaceuticals has been licensed since 2014.
The study is taking place in Israel, it is fully registered with the US NIH under "Cannabics Capsules as Treatment to Improve Cancer Related CACS in Advanced Cancer Patients", Identifier NCT02359123, and may be found at :
https://clinicaltrials.gov/ct2/show/NCT02359123
"The majority of our cancer trial patients have no previous experience with Cannabis, hence this recalibration of the THC level may be more amenable. We believe there is a significant potential medical market for our 5mg THC capsule in countries that have now instituted medical cannabis regulations," said Itamar Borochov, CEO of Cannabics Pharmaceuticals Inc.
http://www.cannabics.com/investors
Market Value1 | $72,404,107 | a/o Jan 13, 2017 | |
Authorized Shares | 900,000,000 | a/o Dec 30, 2016 | |
Outstanding Shares | 107,265,344 | a/o Dec 30, 2016 | |
-Restricted | 90,368,887 | a/o Dec 30, 2016 | |
-Unrestricted | 16,896,457 | a/o Dec 30, 2016 | |
Held at DTC | Not Available | ||
Float | 14,295,638 | a/o Jun 30, 2016 | |
Par Value | 0.0001 |
Market Value1 | $37,994,466 | a/o Oct 28, 2016 | |
Authorized Shares | 900,000,000 | a/o Jul 09, 2015 | |
Outstanding Shares | 107,026,665 | a/o Jun 30, 2016 | |
-Restricted | Not Available | ||
-Unrestricted | Not Available | ||
Held at DTC | Not Available | ||
Float | 18,737,071 | a/o Jun 30, 2016 | |
Par Value | 0.0001 |
PER IHUB MGMT
DISCLAIMER: ONLY FOR MICK
https://investorshub.advfn.com/boards/profilea.aspx?user=1012
*The Board Monitor and herewithin , are not licensed brokers and assume NO responsibility for actions,
investments,decisions, or messages posted on this forum.
CONTENT ON THIS FORUM SHOULD NOT BE CONSIDERED ADVISORY NOR SOLICITATION
AUTHORS MAY HAVE BUYS OR SELLS WITH THE COMPANIES MENTIONED IN TRADING POSTERS SHOULD DUE DILIGENT BUYING OR SELLING.
ALL POSTING SHOULD BE CONSIDERED FOR INFORMATION ONLY. WE DO NOT RECOMMEND ANYONE BUY OR SELL ANY SECURITIES POSTED HEREWITHIN.
ANY trade entered into risks the possibility of losing the funds invested.
• There are no guarantees when buying or selling any security.Any
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |